source
- CAR-T biotech Caribou Biosciences halts two programs and seeks exit after funding shortfallCaribou Biosciences announced it is suspending two of its allogeneic CAR-T cell therapy projects. The company said it could not obtain the financing needed to keep the programs alive and is now lo…
- Experimental exon-skipping drug from Avidity Biosciences shows early improvement in a Duchenne patientA recent story follows two teenage boys living with Duchenne muscular dystrophy, a rare and fatal muscle‑wasting condition. While one boy’s health continues to decline, the other, a 12‑year‑old nam…